A5055714204- Prostate Cancer Treatment and Research
- Sarcoma Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Neuroblastoma Research and Treatments
- Cardiovascular Disease and Adiposity
- Muscle metabolism and nutrition
- Peptidase Inhibition and Analysis
- Urologic and reproductive health conditions
- Radiomics and Machine Learning in Medical Imaging
- Adipose Tissue and Metabolism
University of Twente
2022-2025
Leiden University Medical Center
2019-2025
Leiden University
2024
Abstract Objective Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with varying survival outcomes. This study investigated whether baseline PSMA PET/CT parameters are associated and treatment response. Methods Sixty mCRPC patients underwent [ 18 F]PSMA-1007 before androgen receptor-targeted agents (ARTAs) or chemotherapy. Intensity-based parameters, volumetric metastatic sites DmaxVox (distance between the two outermost voxels) from were collected, as well...
Abstract Purpose Prostate-specific membrane antigen (PSMA) expression has been observed in a subset of soft tissue sarcomas, mainly the neovascular endothelial cells. This feasibility study aimed to evaluate PSMA and PET/CT imaging metastatic sarcoma, providing important insights for potential future exploration PSMA-targeted radioligand therapy. Methods prospective single-center included adult patients with measurable disease (lesion diameter > 1 cm), available biopsy/resection material,...
Current imaging modalities frequently misjudge disease stage in colorectal, gastric and pancreatic cancer. As treatment decisions are dependent on stage, incorrect staging has serious consequences. Previous preclinical research case reports indicate that prostate-specific membrane antigen (PSMA)-targeted PET/CT might provide a solution to some of these challenges. This prospective clinical study aims assess the feasibility [18F]DCFPyL target visualize primary colon, In this trial, patients...